EDITORIAL article
Front. Nutr.
Sec. Clinical Nutrition
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1606634
This article is part of the Research TopicKetogenic Metabolic Therapy as a Treatment for Mental Health DisordersView all 15 articles
Editorial : Ketogenic Metabolic Therapy as a Treatment for Mental Health Disorders
Provisionally accepted- 1Psychology / Neuroscience, Trinity College, Hartford, CT, United States
- 2Ketogenic Therapies, LLC, Milwaukee, Wisconsin, United States
- 3Georgia Ede MD, Northhampton, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Insulin resistance, pre-diabetes, type 2 diabetes, obesity, and other metabolic disorders are becoming increasingly commonplace around the world, and are strongly associated with mental health disorders of many kinds (Hanssen et al., 2024). While metabolic dysfunction negatively impacts all organ systems, the brain is arguably more vulnerable than most, because it is disproportionately metabolically demanding: despite comprising only about 2% of body weight, the brain consumes about 20% of the body's energy supply (Harris et al., 2012).The rapidly emerging field of metabolic psychiatry seeks to understand and address the role metabolic dysfunction plays in mental illness, generating new scientific and clinical insights that are laying the groundwork for a 21st century paradigm shift in mental healthcare. The field urgently needs innovative treatment approaches that can address the metabolic disturbances commonly observed in mental health disorders (and mitigate the metabolic side effects of psychotropic medications), and mounting evidence suggests that ketogenic metabolic therapy has the potential to help meet both of these needs. Successfully used since the 1920s to treat epilepsy, ketogenic metabolic therapy has increasingly become the focus of researchers and clinicians seeking new approaches to a wide variety of other neuropsychiatric disorders as well. This special issue seeks to represent the depth and breadth of work being conducted in this new subspecialty, including theoretical perspectives, mechanistic research, case reports, and clinical trials.Among the original clinical research papers is a retrospective qualitative analysis by Bellamy et al. of people's experiences with calorically unrestricted low-carbohydrate diets, noting benefits such as renewed purpose among those previously experiencing feelings of depression, as well as improvements in self-esteem, confidence and other subjective measures important to quality of life but not often formally assessed in metabolic research.Calabrese et al. present a case series of three adults who achieved complete remission from both treatment-resistant major depressive disorder and generalized anxiety disorder after engaging in a 12-16 week lifestyle protocol centered around a ketogenic diet.Edwards et al. presents the first pilot trial of the ketogenic diet in post-traumatic stress disorder, documenting acceptability and clinical benefits in two of the three individuals who completed the 4-week protocol, and highlighting challenges for future clinical trials.Laurent details the case of a woman with bipolar disorder whose depression had responded only minimally to weekly ketamine treatments. Ketogenic metabolic therapy led to measurable improvements not only in depression, but also in anxiety and PTSD symptoms, as well as in measures of daily function, mental well-being, and quality of life. In a separate perspectives paper, Laurent encourages metabolic psychiatry researchers to collect and analyze both qualitative and quantitative data to present a fuller picture of the impact ketogenic metabolic therapy can have on the lives of people with mental illness.Winje et al. report about a patient with type I diabetes who was able to stabilize blood glucose levels using ketogenic metabolic therapy, reducing fear of hypoglycemia as well as alleviating anxiety and depression symptoms.Especially noteworthy is a paper by Longhitano et al. detailing the protocol they are implementing in a clinical trial involving 100 adults with schizophrenia and bipolar disorder, already under way in Australia. This will be the world's first randomized controlled trial of the ketogenic diet in serious mental illness, therefore their findings are eagerly anticipated.Additional articles offer perspectives on the potential utility of ketogenic diets in the management of neuropsychiatric conditions beyond mood and psychotic disorders.An intriguing review paper by Frank and Scolnick presents hopeful emerging evidence suggesting that properly formulated ketogenic diets, despite commonly being viewed as weight loss interventions, may support people in their recovery from anorexia nervosa, a condition with a high fatality rate and no approved biological treatment.Ruskin et al. explore how ketosis positively influences the adenosine system, the dopamine system, and relevant factors such as inflammation, thereby representing a long-overlooked opportunity to support people suffering with addictive disorders. O'Hearn offers a conceptual analysis of the relationship between energy status, metabolic state, and sleep regulation which may help to explain the positive effect of ketosis on sleep quality. Stanton puts forth hypotheses on how well-formulated ketogenic and carnivore diets could stabilize certain factors associated with migraine headaches. Grabowska et al. point out, based on a review of 90 studies of the ketogenic diet conducted in rodent models, that behavioral health outcomes such as anxiety and depression have been less promising in these animal models than those observed in human case reports and clinical trials, a phenomenon also observed in epilepsy research (Bough and Rho, 2007).Gertler and Blackford highlight the underexplored potential of ketogenic metabolic therapy in the management of pediatric mental and metabolic health disorders, particularly those that often coexist in children with epilepsy such as ADHD, autism spectrum disorder, and childhood obesity.Diamond et al. challenge the widespread concern that ketogenic diets jeopardize cardiovascular health because they are high in fat and sometimes lead to elevations in LDL cholesterol-a persistent obstacle to wider acceptance of ketogenic diets by clinicians and patients alike.The Centers for Disease Control estimate that more than 50% of Americans will be diagnosed with a mental health disorder in their lifetime (CDC Data and Statistics, 2025), so the need for novel approaches to understanding, treating, and perhaps even preventing these burdensome conditions could not be more urgent. The papers curated for this special issue represent a diversity of efforts aimed at improving the lives of individuals with a diversity of neuropsychiatric conditions through innovative research into brain metabolism and the supervised incorporation of ketogenic metabolic therapy into clinical care. These works strengthen our understanding of the important relationship between metabolic health and mental health, and contribute to the growing sense that ketogenic metabolic therapy is emerging as a powerful, low-risk, lifestyle-based tool that could be integral in paving the path to a more hopeful future for mental health practitioners and the patients they serve.
Keywords: Ketogenic Diet, metabolic psychiatry, Schizophrenia, Bipolar Disorder, Addiction, clinical research, Translational research
Received: 06 Apr 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Masino, Zupec-Kania and Ede. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Susan A Masino, Psychology / Neuroscience, Trinity College, Hartford, 06106, CT, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.